Minafin has strengthened the industrial and commercial base of its healthcare chemicals division with the acquisition of Delmar in Montreal, Canada. This operation enables Minakem to establish itself on North American soil for the first time in its history, with a site approved by U.S. and international drug agencies for the manufacture of active pharmaceutical ingredients (APIs) by organic synthesis.

Delmar also brings an important portfolio of generic active ingredients, which will accelerate Minakem generics and new therapies’ development in the North American generic market and strengthen its offering of generic active ingredients for all its customers.

The 100-person-strong Montreal site brings new R&D, industrial transposition, and commercial manufacturing resources, which are integrated as Minakem Montreal alongside those of the Beuvry-la-Forêt, Dunkerque and Louvain-la-Neuve sites within the industrial department of the health chemicals division.

In particular, the Minakem Montréal site adds significant R&D capabilities, with an experienced team and a well-equipped laboratory, supported by substantial analytical development resources. In terms of organic synthesis, the Montreal plant brings 174 cubic meters of reaction capacity, a plant dedicated to corticosteroid synthesis, manufacturing permits for controlled substances and the veterinary active ingredients market, all of which are highly complementary to the capabilities of the European sites.